Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/22/2850987/0/en/Theratechnologies-Announces-Update-on-its-Preclinical-Oncology-Research-Program.html
https://www.globenewswire.com/news-release/2024/03/22/2850716/0/en/Theratechnologies-Appoints-Jordan-Zwick-to-its-Board-of-Directors.html
https://www.globenewswire.com/news-release/2024/03/21/2850128/0/en/Theratechnologies-Initiates-Increased-Dose-Level-in-Phase-1-Clinical-Trial-of-Sudocetaxel-Zendusortide-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com//news-release/2024/02/29/2838447/0/en/Theratechnologies-Announces-the-Resignation-of-One-of-Its-Directors-Mr-Alain-Trudeau.html
https://endpts.com/theratechnologies-hit-with-fda-refuse-to-file-letter-for-intramuscular-version-of-hiv-drug/
https://www.globenewswire.com//news-release/2024/02/21/2832658/0/en/Theratechnologies-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-of-Fiscal-2023-and-Provides-2024-Guidance.html
https://www.globenewswire.com//news-release/2024/02/20/2831717/0/en/Theratechnologies-Announces-Publication-in-Frontiers-in-Immunology-that-Deepens-Understanding-of-Sudocetaxel-Zendusortide-TH1902-Molecular-Mechanism-of-Action.html
https://www.globenewswire.com//news-release/2024/02/15/2829853/0/en/Theratechnologies-Completes-Enrollment-of-First-Six-Patients-in-Updated-Phase-1-Clinical-Trial-of-Sudocetaxel-Zendusortide-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com//news-release/2024/02/06/2824182/0/en/Theratechnologies-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Business-Update.html
https://www.globenewswire.com/news-release/2024/01/24/2815109/0/en/Theratechnologies-Receives-Complete-Response-Letter-CRL-from-the-FDA-for-the-F8-Formulation-of-Tesamorelin-sBLA.html